SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial (RILY) is trending after filing its Q3 financial results, showcasing renewed profitability and NASDAQ compliance. This development has ignited intense community discussion around a potential short and gamma squeeze, with many comparing it to past explosive market events due to high short interest and a constrained float.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending after securing approval for an additional 830 megawatts at its Helios Data Center Campus, doubling its total power capacity to over 1.6 Gigawatts. The community is hailing this as a game-changing development, significantly re-rating GLXY's valuation as a key hybrid player in both the institutional crypto market and the burgeoning AI infrastructure sector.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings (SPHL) is experiencing intense investor interest driven by a newly announced strategic partnership for solar and green-energy solutions in Singapore. The community is actively discussing the stock's extremely low float, fueling speculation about significant short squeeze potential and prompting expectations of highly volatile price action. While many anticipate a substantial upward move, a segment of traders urges caution, referencing the ticker's history of sharp price fluctuations.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is actively discussed after its substantial $200 million investment in Beast Industries, founded by YouTube star MrBeast. This strategic pivot has sparked intense debate among investors, with many questioning the allocation of capital away from core Ethereum holdings and share buybacks. Others view it as a forward-thinking move to attract younger demographics and expand into future crypto-backed ventures, further fueling community discussion around an upcoming vote on a significant increase in authorized shares.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor Manufacturing is trending strongly after delivering an impressive earnings report that surpassed expectations, fueled by robust demand for advanced AI chips. The semiconductor giant's optimistic guidance and substantial capital expenditure plans are widely viewed by the community as a powerful affirmation of the accelerating AI infrastructure build-out. This performance is boosting sentiment across the broader semiconductor sector and reinforcing confidence in the long-term AI megatrend.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical ($DRTS) is trending amidst high anticipation for imminent Japanese regulatory approval and a key presentation at a major healthcare conference this week, further bolstered by recent compelling pancreatic cancer data. The community is actively discussing the stock's pioneering Alpha DaRT technology and its life-saving potential in difficult-to-treat cancers, believing it remains significantly undervalued as it garners increasing institutional interest and ETF attention.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

CNSP is trending due to its recent Orphan Drug designation for TPI-287, a treatment for brain cancer, sparking excitement around potential upside. The community is actively discussing the stock's low float and potential for a squeeze, with some analysts targeting significantly higher prices. Despite a history of reverse stock splits, the focus remains on the potential of CNSP's glioblastoma pipeline.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q32 Bio (NASDAQ:QTTB) CFO Lee Kalowski Sells 9,072 Shares

Q32 Bio Inc. (NASDAQ:QTTB - Get Free Report) CFO Lee Kalowski sold 9,072 shares of the business's stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $3.46...

Best Biotech Stocks To Research - December 1st

Q32 Bio, Cidara Therapeutics, Danaher, argenex, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of...

Medical Stocks To Research - December 1st

Eli Lilly and Company, UnitedHealth Group, Pfizer, Q32 Bio, and Johnson & Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares...

<ul class="summary-bullets"><li>ADX-097 is designed to inhibit complement activation, an integral part of the innate immune system, and has potential across kidney, autoimmune, vascular and skin diseases.</li><li>Q32 Bio is also eligible to receive tiered royalties on potential future sales of ADX-097, ranging from low single-digit to mid-teen percentages.</li><li>The company is now focussed on advancing Bempikibart for patients with alopecia areata.</li></ul> Shares of Q32 Bio Inc. (QTTB) jumped 98% on Monday after the company sold its experimental drug ADX-097, to Akebia Therapeutics, Inc. (AKBA) for up to $592 million.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.q32bio.com/news-releases/news-release-details/q32-bio-sells-complement-inhibitor-adx-097">said</a> that the sale extends its cash runway into the second half of 2027. ADX-097 is designed to inhibit complement activation, an integral part of the innate immune system, and has potential across kidney, autoimmune, vascular and skin diseases.<h2 class="st-heading-2">Terms Of The Deal</h2>Akebia will now be responsible for future development and commercialization of ADX-097. Under the deal, Q32 Bio will receive $12 million in upfront payments and near-term milestone payments.These payments as well as potential development, regulatory and commercial milestones total up to $592 million, the company said. Q32 Bio is also eligible to receive tiered royalties on potential future sales of ADX-097, ranging from low single-digit to mid-teen percentages.ADX-097 is the lead product candidate from Q32 Bio's tissue-targeted complement inhibitor platform. Q32 Bio, however, retains the rights to the platform, including ADX-096 being developed for ophthalmologic indications and other remaining early-stage assets and is continuing to evaluate strategic options for these programs.The company is now focussed on advancing Bempikibart for patients with alopecia areata, an autoimmune disorder that causes the immune system to attack hair follicles, resulting in sudden, patchy hair loss, most commonly on the scalp.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QTTB">QTTB stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:586/57;" src="data:image/png;base64,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" alt="QTTB’s Sentiment Meter and Message Volume as of 12:40 p.m. ET on Nov. 28, 2025 | Source: Stocktwits" width="586" height="57"><figcaption>QTTB’s Sentiment Meter and Message Volume as of 12:40 p.m. ET on Dec. 1, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the deal opening opportunities for the company.<stembedurl>https://stocktwits.com/topstockalerts/message/637812919</stembedurl>QTTB stock is up by 26% this year but down by about 84% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/connecticut-attorney-general-presses-bnpl-firms-paypal-sezzle-on-fees-disclosure-debt-risks/cLI71TxREiD">Connecticut Attorney General Presses BNPL Firms PayPal, Sezzle On Fees, Disclosures And Debt Risks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M

The company said that the sale extends its cash runway into the second half of 2027.

Equity

The company said that the sale extends its cash runway into the second half of 2027.


<ul class="summary-bullets"><li>Moderna shares were down around 6% in Monday’s midday trade after the U.S. Food and Drug Administration outlined stricter vaccine approval rules in an internal memo last week.</li><li>Strategy shares were down more than 11% in Monday’s midday session after Bitcoin prices fell below $84,000.</li><li>Q32 Bio shares were up more than 100% in Monday’s midday trade after the company announced the sale of its Phase 2 complement inhibitor to Akebia Therapeutics.</li></ul>U.S. equities were down in Monday’s midday trade, beginning December on a negative note, even as Wall Street keeps an eye out for commentary from Federal Reserve Chair Jerome Powell later in the day.Tom Lee, Managing Partner at Fundstrat Global Advisors, on Monday laid out his&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fundstrat-tom-lee-sp-500-prediction-climb-7300-in-december/cLI7gvmREiN">bull thesis</a> for the S&amp;P 500 heading into the year-end, listing seasonal tailwinds and a boost to equities from the Fed’s monetary policy decision as the two reasons behind his optimism.“I think the biggest tailwind that’s going to emerge in the next couple of weeks is around the central bank. The Fed is set to cut in December,” Lee said.According to data from the CME FedWatch&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, the probability of a 25-basis-point rate cut in December has increased to 87.6%, up from 84.4% a week ago.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.28% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, fell 0.34%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.42%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Monday’s midday trade:</h2><a href="https://stocktwits.com/symbol/SNPS">Synopsys Inc. (SNPS)</a>Synopsys shares were up nearly 4% in Monday’s midday session after AI bellwether Nvidia Corp. (NVDA)&nbsp;<a href="http://stocktwits.com/news-articles/markets/equity/synopsys-pops-after-nvidia-takes-2-billion-stake/cLI7XITREij">announced</a> a $2 billion investment in the company. As part of the partnership, Nvidia’s AI capabilities will be paired with Synopsys’ engineering software to help in designing, simulating, and verifying products faster.<a href="https://stocktwits.com/symbol/SNPS">SNPS stock</a> is down 11% year-to-date.<a href="https://stocktwits.com/symbol/MRNA">Moderna Inc. (MRNA)</a>Moderna shares were down around 6% in Monday’s midday trade after the U.S. Food and Drug Administration (FDA) outlined stricter vaccine approval rules in an internal memo last week, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.barrons.com/articles/moderna-and-novavax-stocks-drop-as-fda-proposes-stricter-vaccine-approvals-beba1a96">report</a> by Barron’s. Novavax Inc. (NVAX) and BioNTech SE’s (BNTX) shares were down 4% each.<a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> is down 42% year to date.<a href="https://stocktwits.com/symbol/MSTR">Strategy Inc. (MSTR)</a>Strategy shares were down more than 11% in Monday’s midday session after Bitcoin (BTC) prices fell below $84,000. At the time of writing, Bitcoin was down nearly 8% over the past 24 hours. The decline in Bitcoin prices triggered nearly $1 billion in&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-falls-to-84000-1-billion-wiped-out-mstr-bmnr-lead-crypto-stocks-selloff/cLI71d2REix">liquidations</a> in the last 24 hours.<a href="https://stocktwits.com/symbol/MSTR">MSTR stock</a> is down 45% year to date.<a href="https://stocktwits.com/symbol/QTTB">Q32 Bio Inc. (QTTB)</a>Q32 Bio shares were up more than 100% in Monday’s midday trade after the company announced the sale of its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics Inc. (NASDAQ: AKBA). As part of the deal, Q32 is eligible to receive up to $592 million upon achievement of certain milestones, including $12 million upfront.<a href="https://stocktwits.com/symbol/QTTB">QTTB stock</a> is up 27% year-to-date.<a href="https://stocktwits.com/symbol/WOLF">Wolfspeed Inc. (WOLF)</a>Wolfspeed shares were up around 8% in Monday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-wolfspeed-stock-rise-7-today/cLI7K6PREiw">announced</a> the receipt of $698.6 million in cash tax refunds from the Internal Revenue Service (IRS).<a href="https://stocktwits.com/symbol/WOLF">WOLF stock</a> is up 21% year to date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-cuts-zepbound-weight-loss-drug-prices-to-299-a-month/cLI7QykREih">Eli Lilly Cuts Prices For Weight Loss Drug Zepbound To $299 A Month As It Takes On Novo Nordisk’s Wegovy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today

Synopsys shares were up nearly 4% in Monday’s midday session after AI bellwether Nvidia announced a $2 billion investment in the company.

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.read more...

Q32 Bio Sells Complement Inhibitor ADX-097

Q32 Bio Sells Complement Inhibitor ADX-097 Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire WALTHAM, Mass., Dec. 1, 2025 -- Asset sale further enables Company's strategic focus on advancing...

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov...

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a...

Retail investor interest in Q32 Bio Inc picked up on Wednesday after the clinical-stage biotech said the U.S. Food and Drug Administration granted Fast Track designation to its experimental treatment for alopecia areata.The drug, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody being tested in a Phase 2 trial for alopecia areata (AA), an autoimmune disorder that causes hair loss.&nbsp;The Fast Track status is intended to speed development of therapies that address serious conditions and unmet medical needs."The Fast Track designation granted by the FDA recognizes the seriousness of AA and the significant current unmet medical need while underscoring bempikibart's potential as a novel, differentiated therapy," said Q32 Bio Chief Executive Jodie Morrison in a statement.Bempikibart is designed to re-regulate immune function by blocking IL-7 and TSLP signaling pathways, key components in autoimmune activity.&nbsp;The company recently began dosing patients in both an open-label extension and Part B of its SIGNAL-AA trial following encouraging early results.The FDA designation allows for more frequent meetings with the agency, eligibility for priority review, and the possibility of accelerated approval, subject to clinical results.On Stocktwits, 24-hour message volume for Regulus jumped by 1,600% amid bullish sentiment.Some users highlighted the stock’s low float and recent FDA news as drivers for a potential swing trade, while others noted that the therapy itself — bempikibart — is making steady clinical progress.&nbsp;<stembedurl>https://stocktwits.com/onlyfactshere/message/613083538</stembedurl>One user pointed to the Fast Track status as a key catalyst, potentially accelerating development timelines for a treatment area with few approved options.&nbsp;<stembedurl>https://stocktwits.com/ALOSETE/message/613089756</stembedurl>Still, some cautioned that despite promising Phase 2 data, the company’s limited cash runway — estimated at about five quarters — underscores the inherent risks of biotech investing.<stembedurl>https://stocktwits.com/Rage_Against_The_Machine/message/613078123</stembedurl>Shares of Q32 Bio have declined 1.9% year-to-date, underperforming the Nasdaq, which is down 1.6%, but faring better than the Dow and S&amp;P 500, which have fallen 4.1% and 5.1%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug

Q32 Bio shares drew renewed attention on Wednesday after the FDA granted Fast Track designation to its experimental alopecia areata treatment, bempikibart. The designation could accelerate development and review of the Phase 2-stage therapy.

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$3.57
Prev Close	$3.60
Open	$3.58
Dividend Yield	0.00%
50-Day Moving Average	$2.90
Beta	0.58
Avg. Volume	8.3M
PE Ratio	-1.04

52-Week High	$6.37
52-Week Low	$1.35
Market Capitalization	$44.3M
EPS (Annual)	-$6.58
Price to Book	-2.40
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

QTTB
Q32 Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QTTB News

QTTBQ32 Bio Inc.